## Yun Ling

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4449394/publications.pdf

Version: 2024-02-01

331670 254184 5,655 44 21 43 citations h-index g-index papers 49 49 49 14370 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology, 2020, 295, 210-217.	7.3	997
2	Viral and host factors related to the clinical outcome of COVID-19. Nature, 2020, 583, 437-440.	27.8	746
3	COVID-19 with Different Severities: A Multicenter Study of Clinical Features. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1380-1388.	<b>5.</b> 6	690
4	Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chinese Medical Journal, 2020, 133, 1039-1043.	2.3	686
5	Clinical progression of patients with COVID-19 in Shanghai, China. Journal of Infection, 2020, 80, e1-e6.	3.3	627
6	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Internal Medicine, 2020, 180, 1356.	5.1	211
7	Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. Journal of Experimental Medicine, 2015, 212, 619-631.	8.5	162
8	Blood molecular markers associated with COVIDâ€19 immunopathology and multiâ€organ damage. EMBO Journal, 2020, 39, e105896.	7.8	123
9	Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19. Open Forum Infectious Diseases, 2020, 7, ofaa241.	0.9	97
10	Pre-optimized phage therapy on secondary <i>Acinetobacter baumannii</i> infection in four critical COVID-19 patients. Emerging Microbes and Infections, 2021, 10, 612-618.	6.5	80
11	Mitochondrial Sirtuin 4 Resolves Immune Tolerance in Monocytes by Rebalancing Glycolysis and Glucose Oxidation Homeostasis. Frontiers in Immunology, 2018, 9, 419.	4.8	69
12	Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study. Phytomedicine, 2021, 85, 153390.	5.3	60
13	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Emerging Microbes and Infections, 2020, 9, 1988-1996.	6.5	58
14	Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Frontiers of Medicine, 2020, 14, 746-751.	3.4	57
15	Clinical Potential of <scp>UTEâ€MRI</scp> for Assessing <scp>COVID</scp> â€19: Patient―and Lesionâ€Based Comparative Analysis. Journal of Magnetic Resonance Imaging, 2020, 52, 397-406.	3.4	48
16	An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants. Emerging Microbes and Infections, 2022, 11, 1518-1523.	6.5	42
17	Integrated analysis of gut microbiome and host immune responses in COVID-19. Frontiers of Medicine, 2022, 16, 263-275.	3.4	35
18	An inter-correlated cytokine network identified at the center of cytokine storm predicted COVID-19 prognosis. Cytokine, 2021, 138, 155365.	3.2	30

#	Article	lF	CITATIONS
19	Epigenetic Landscapes of Single-Cell Chromatin Accessibility and Transcriptomic Immune Profiles of T Cells in COVID-19 Patients. Frontiers in Immunology, 2021, 12, 625881.	4.8	30
20	Observations about symptomatic and asymptomatic infections of 494 patients with COVID-19 in Shanghai, China. American Journal of Infection Control, 2020, 48, 1045-1050.	2.3	28
21	Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals. Cell Discovery, 2021, 7, 89.	6.7	27
22	Switch of NAD Salvage to de novo Biosynthesis Sustains SIRT1-RelB-Dependent Inflammatory Tolerance. Frontiers in Immunology, 2019, 10, 2358.	4.8	25
23	Dynamic anti-spike protein antibody profiles in COVID-19 patients. International Journal of Infectious Diseases, 2021, 103, 540-548.	3.3	25
24	A simple algorithm helps early identification of SARS-CoV-2 infection patients with severe progression tendency. Infection, 2020, 48, 577-584.	4.7	25
25	Epidemiology and clinical course of COVID-19 in Shanghai, China. Emerging Microbes and Infections, 2020, 9, 1537-1545.	6.5	24
26	Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding. Journal of Pharmaceutical and Biomedical Analysis, 2021, 196, 113927.	2.8	23
27	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. Cell Discovery, 2021, 7, 42.	6.7	23
28	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-κ plus TFF2 in patients with moderate COVID-19. EClinicalMedicine, 2020, 25, 100478.	7.1	20
29	Application of ordinal logistic regression analysis to identify the determinants of illness severity of COVID-19 in China. Epidemiology and Infection, 2020, 148, e146.	2.1	20
30	The Course of Mild and Moderate COVID-19 Infectionsâ€"The Unexpected Long-Lasting Challenge. Open Forum Infectious Diseases, 2020, 7, ofaa286.	0.9	19
31	Correlation Between Early Plasma Interleukin 37 Responses With Low Inflammatory Cytokine Levels and Benign Clinical Outcomes in Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2021, 223, 568-580.	4.0	17
32	A streamlined clinical metagenomic sequencing protocol for rapid pathogen identification. Scientific Reports, 2021, 11, 4405.	3.3	15
33	Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduction and Targeted Therapy, 2022, 7, 91.	17.1	14
34	Co-infection in COVID-19, a cohort study. Journal of Infection, 2021, 82, 414-451.	3.3	11
35	Genetic and Clinical Profiles of Disseminated Bacillus Calmette-Guérin Disease and Chronic Granulomatous Disease in China. Frontiers in Immunology, 2019, 10, 73.	4.8	10
36	Analysis of risk factors of PICC-related bloodstream infection in newborns: implications for nursing care. European Journal of Medical Research, 2021, 26, 80.	2.2	10

#	Article	IF	Citations
37	Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19. BioScience Trends, 2020, 14, 161-167.	3.4	8
38	Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19. Journal of Inflammation Research, 2021, Volume 14, 287-298.	3.5	5
39	Case report: histopathology and molecular pathology analysis on enteric tissue of a COVID-19 patient. Diagnostic Pathology, 2021, 16, 40.	2.0	3
40	Risk factors for myocardial injury at admission of 325 patients with coronavirus disease 2019 in Shanghai, China. Australasian Journal on Ageing, 2021, , .	0.9	3
41	Immune profiles of a COVID-19 adolescent with mild symptoms and anti-viral antibody deficiency. Fundamental Research, 2021, 1, 117-123.	3.3	2
42	Clinical Immunophenotype at Disease Onset in Previously Healthy Patients With Cryptococcal Meningitis. Medicine (United States), 2016, 95, e2744.	1.0	1
43	纳米å"æµ‹åºæŠ€æœ¯åœ¨é‡ç—‡æ–°å†è,ºç,Žæ,£è€ç»§å'感染诊æ–ä¸çš"应用. Zhejiang Da Xue Xue Bao \	'i <b>Xue</b> Ban	= <b>j</b> ournal of
44	Preliminary investigation of relationship between clinical indicators and CT manifestation patterns of COVID-19 pneumonia improvement. Journal of Thoracic Disease, 2020, 12, 5896-5905.	1.4	0